<DOC>
	<DOCNO>NCT00384384</DOCNO>
	<brief_summary>Background : 18B Glycyrrhetinic acid ( active compound Licorice ) decrease serum potassium via enhanced renal potassium loss healthy individual thereby induce renal sodium retention arterial hypertension.In dialysis patient mechanism disturb compensatory intestinal potassium secretion enhance . 18B Glycyrrhetinic acid inhibitor 11B Hydroxysteroid dehydrogenase type 1 ( 11b HSD1 ) . Inhibition 11 b HSD1 offer novel potential therapy lower intracellular cortisol concentration thereby enhance insulin sensitivity . Hypothesis : Glycyrrhetinic acid decrease serum potassium enhance intestinal excretion dialysis patient increase insulin sensivity inhibition 11b HSD Methods : double blind , 6 month cross trial compare oral 18b Glycyrrhetinic acid placebo 24 nondiabetic dialysis patient . Endpoints : predialytic serum potassium level , insuline sensitivity assess fast glucose fasting insulin concentration</brief_summary>
	<brief_title>Glycyrrhetinic Acid-Effect Serum Potassium Insulin Resistance Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Glycyrrhetinic Acid</mesh_term>
	<criteria>dialysis patient ( &gt; 3 month ) diabetic hospital stay last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Dialysis</keyword>
	<keyword>Serum potassium</keyword>
	<keyword>18b glycyrrhetinic acid</keyword>
	<keyword>insulin sensitivity</keyword>
</DOC>